Abstract
The activity of ten 4-quinolone drugs was tested against fiveEscherichia coli mutants. Mutational resistance was found to reduce the activity of all ten drugs, indicating that they display biochemical cross-resistance with each other. However, ciprofloxacin and, to a lesser extent, ofloxacin and norfloxacin were so highly active that the most resistance exhibited by any mutant fell well within the serum drug concentration ranges attainable in humans. Hence, clinical cross-resistance inEscherichia coli at least, need not necessarily apply to such highly active 4-quinolone antibacterial agents.
Similar content being viewed by others
References
Crumplin, G. C., Smith, J. T.: The effect of R-factor plasmids on host-cell responses to nalidixic acid I. Increased susceptibility of nalidixic acid-sensitive hosts. Journal of Antimicrobial Chemotherapy 1981, 7: 379–388.
Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., Tomizawa, J.-I.: Nalidixic acid resistance: A second character involved in DNA gyrase activity. Proceedings of the National Academy of Sciences of the USA 1977, 74: 4772–4776.
Hane, M., Wood, T.:Escherichia coli K12 mutants resistant to nalidixic acid: Genetic mapping and dominance studies. Journal of Bacteriology 1969, 99: 238–241.
Inoue, S., Ohue, T., Yamagishi, J., Nakamura, S., Shimizu, M.: Mode of incomplete cross resistance among pipemidic, piromidic and nalidixic acids. Antimicrobial Agents and Chemotherapy 1978, 14: 240–245.
Crumplin, G. C., Midgley, J. M., Smith, J. T.: Mechanism of action of nalidixic acid and its congeners. In: Sammes, P. (ed.): Topics in antibiotic chemistry. Volume 3. Ellis Horwood Ltd., Chichester, England, 1980, p. 11–38.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, J.T. Mutational resistance to 4-quinolone antibacterial agents. Eur. J, Clin. Microbiol. 3, 347–350 (1984). https://doi.org/10.1007/BF01977492
Issue Date:
DOI: https://doi.org/10.1007/BF01977492